Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.33 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158470 | 0.86 | MAPT (0.43) | MAPTPKMHSD17B2GPR88 | |
| SCHEMBL5156709 | 0.77 | MAPT (0.44) | MAPTPKM | |
| SCHEMBL5161638 | 0.75 | CYP2C19 (0.41) | MAPTPKMHSD17B2ALDH1A1 | |
| SCHEMBL5159699 | 0.72 | MAPT (0.38) | MAPTPKMGPR88KDM4EALDH1A1 | |
| SCHEMBL5159691 | 0.72 | MAPT (0.39) | MAPTPKMNQO2ALOX5KDM4E | |
| SCHEMBL5176933 | 0.71 | MAPT (0.43) | MAPTPKM | |
| SCHEMBL6484350 | 0.71 | MAPT (0.41) | MAPTPKMHSD17B2GPR88ALDH1A1 | |
| SCHEMBL5156159 | 0.67 | MAPT (0.46) | MAPTPKMHSD17B2 | |
| SCHEMBL10675560 | 0.65 | REN (0.51) | MAPTPKMALDH1A1 | |
| SCHEMBL10675547 | 0.65 | REN (0.51) | MAPTPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | MAPT 2851/4885PKM 609/4885HSD17B2 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.